Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 17, 2026

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Performance

52-Week Range 44.3% below 52-week high

15.20

12.4352W Low 27.3052W High

1 Week 9.5% below 1-week high

15.091W Low 16.801W High

Dyne Therapeutics, Inc. - Common Stock (DYN) traded between $12.43 and $27.30 over the past 52 weeks and last traded at $15.20, 44.3% below its 52-week high. Over the past week it ranged between $15.09 and $16.80.

Past 12 Months

-7.0%

-37.4%

-33.5%

-17.2%

-17.8%

+20.2%

1W -$1.14

1M -$9.08

3M -$7.64

6M -$3.15

YTD -$3.30

1Y +$2.55

DYN was +20.2% over the past year, -17.2% over six months, -17.8% year to date, -7.0% in the last week.

12 Months vs Market

DYN

+20.2%

DIA

+9.5%

SPY

+14.6%

QQQ

+23.3%

IWM

+14.1%

Over the past 12 months DYN returned +20.2% versus DIA (Dow) +9.5%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 0.00× 3-mo avg

Today 415 3-mo avg 2.7M

3.1M

3.9M

2.7M

2.3M

YTD

2.3M

2.4M

DYN most recently traded 415 shares against a 3-month average daily volume of 2.7M.

More News

There are notable gap-ups and gap-downs in today's session. ↗

September 08, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

September 08, 2026

Via Chartmill

September 08, 2026

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

September 03, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

July 29, 2026

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

July 28, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2026

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

July 23, 2026

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

July 21, 2026

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

July 21, 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

July 20, 2026

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗

July 04, 2026

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗

July 01, 2026

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 26, 2026

Dyne Therapeutics Appoints Barry Greene to Board of Directors

June 22, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 18, 2026

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

June 17, 2026

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

June 03, 2026

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

May 26, 2026